01/09/2015 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
12/29/2014 ADOCIA announces its financial calendar for 2015 Icon check
12/22/2014 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Icon check
12/19/2014 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Icon check
10/16/2014 ADOCIA Announces Third-quarter Financial 2014 Results Icon check
09/30/2014 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry Icon check
09/09/2014 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes Icon check
08/25/2014 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer Icon check
07/24/2014 Adocia Reports Operational and Financial Results for the First Half of 2014 Icon check
07/10/2014 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
07/09/2014 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes Icon check
06/24/2014 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only)
06/16/2014 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only)
06/14/2014 Résiliation du contrat de liquidité avec DSF Markets Icon check
06/13/2014 “Pharmacokinetic (PK) and Pharmacodynamic (PD) Characteristics of BioChaperone Combo (BC Combo), the First Fixed Combination of Glargine and Lispro, in Type 1 Diabetes”, (Poster 83-LB), presented by Dr. Ulrike Hövelmann, 74th Scientific Sessions American Diabetes Association 13-17 June 2014, San Francisco, CA, (USA)
06/13/2014 “The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)
06/10/2014 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Icon check
06/04/2014 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014
05/27/2014 Adocia initiates ADR program in the United States Icon check
05/20/2014 Adocia: PR BC Lispro Initiation of phase 2a Icon check
05/19/2014 Adocia Press Release Liquidity Agreement with Kepler Icon check
05/06/2014 Termination of Liquidity Agreement with DSF Markets Icon check
04/10/2014 Adocia: Ultra Fast Lispro Clinical Results Icon check
04/10/2014 Adocia: Revenue Q1 2014 Icon check
03/26/2014 Gerard Soula Interview – La bourse et la vie (Transcript)
03/20/2014 Adocia: Annual results 2013 Icon check
03/17/2014 Adocia: confirmation of positive clinical results Combo Icon check
02/26/2014 Positive Clinical Results for Combo Icon check
02/10/2014 Adocia: Annual revenue of EUR 5.6 M in 2013 Icon check
01/29/2014 2014 Financial Calendar
01/20/2014 Half year report on Adocia’s liquidity agreement at December 2013 Icon check
01/13/2014 Adocia strengthens its diabetic foot ulcer patent portfolio
01/06/2014 Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin
12/09/2013 Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors Icon check
11/13/2013 Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog Icon check
10/24/2013 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Icon check
10/19/2013 Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère
09/05/2013 Activity and results for the first half of 2013 Icon check
07/29/2013 Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration Icon check
07/15/2013 Half Year report on Adocia’s Liquidity agreement with BIL Finance Icon check
04/26/2013 Release of 2012 Reference Document (French only) Icon check
04/24/2013 Q1 2013 revenues Icon check
04/23/2013 Liquidity agreement Icon check
04/23/2013 PR Suspension liquidity agreement Icon check
03/26/2013 Adocia announces release of 2012 Reference document (French only) Icon check
03/20/2013 2012 Annual Results Icon check
03/18/2013 Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency Icon check
02/13/2013 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Icon check
01/07/2013 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Icon check
10/30/2012 Adocia announces the strong growth of its turnover Icon check
Join our mailing list. Subscribe